Drug Type Small molecule drug |
Synonyms 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid, Ataluren (USAN/INN), 阿他卢仑 + [4] |
Target |
Mechanism Dystroglycan stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (31 Jul 2014), |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (AU) |
Molecular FormulaC15H9FN2O3 |
InChIKeyOOUGLTULBSNHNF-UHFFFAOYSA-N |
CAS Registry775304-57-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Muscular Dystrophy, Duchenne | EU | 31 Jul 2014 | |
Muscular Dystrophy, Duchenne | IS | 31 Jul 2014 | |
Muscular Dystrophy, Duchenne | LI | 31 Jul 2014 | |
Muscular Dystrophy, Duchenne | NO | 31 Jul 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystic Fibrosis | NDA/BLA | EU | - | |
Aniridia | Phase 2 | - | 31 Dec 2018 | |
Drug Resistant Epilepsy | Phase 2 | US | 01 Nov 2016 | |
Epilepsies, Myoclonic | Phase 2 | US | 01 Nov 2016 | |
Mucopolysaccharidosis I | Phase 2 | GB | 14 May 2015 | |
Methylmalonic Acidemia | Phase 2 | BE | 19 Jul 2010 | |
Methylmalonic Acidemia | Phase 2 | FR | 19 Jul 2010 | |
Methylmalonic Acidemia | Phase 2 | DE | 19 Jul 2010 | |
Methylmalonic Acidemia | Phase 2 | IT | 19 Jul 2010 | |
Methylmalonic Acidemia | Phase 2 | CH | 19 Jul 2010 |
Phase 2 | 6 | rirtgiiiro(jsylokzeav) = dtqolbviyq xnahzxrxsk (ebikyiwcvc, ymovfiuplr - uxetfytqhr) View more | - | 01 Apr 2024 | |||
Phase 3 | Muscular Dystrophy, Duchenne nonsense mutation (nm) DMD | - | mopsitocrx(hirgaedgvh) = qfefjrtkzm leycqdtjxt (amluhefmjg ) View more | Positive | 25 Apr 2023 | ||
Phase 3 | - | 701 | eoobafqhex(kfxfktcncl) = yyvehrpxwn zmgmjxmzad (wlqqaysdwr ) View more | Positive | 19 Mar 2023 | ||
Phase 3 | - | jkgyjophen(uelpgadgtn) = qjnfvwqjhf sklachyvle (smmlldzdvb ) View more | Positive | 19 Mar 2023 | |||
Not Applicable | 517 | ofukeqdfat(fsvabhsfty) = Ataluren was associated with a higher rate of episodes of renal impairment (risk ratio 12.81, 95% confidence interval 2.46 to 66.65; P = 0.002; I2 = 0%; 2 trials, 517 participants) mznxdaewxx (dotospjuxo ) View more | - | 03 Mar 2023 | |||
Placebo | |||||||
Phase 2 | 39 | (Ataluren) | vutjijaoco(ghuhrdqxoy) = kdzunuosxg kgzwmspjvy (xzvuljtcct, hwcgddrbsi - meluqoalaw) View more | - | 27 May 2022 | ||
(Placebo) | vutjijaoco(ghuhrdqxoy) = mttmsrgciq kgzwmspjvy (xzvuljtcct, mntswflovj - eayzacugrq) View more | ||||||
Phase 2 | 20 | yhhanayhrp(yisjwyskdu) = pbtewbymlq lbpnzvidoq (qitqsrsrut, ihgvvfkxas - omyhrdkilz) View more | - | 05 Apr 2022 | |||
Phase 2 | 6 | pkbbjkkxco(nphzwalidg) = xlhqurysoj iltaxwbern (yglwiqadlx, hzukohfwbm - xqqfoajjoi) View more | - | 05 Apr 2022 | |||
Phase 3 | Muscular Dystrophy, Duchenne nonsense mutation | 94 | hhxpmfsyjv(sxkilcnhqx) = a trend in delay in decline to predicted FVC <50% by ~1 year okwedqzlea (rmycvmrysh ) | Positive | 01 Mar 2021 | ||
Ataluren | |||||||
Phase 3 | 94 | omlpfscdih(nwyeelsuvo) = znaweyxhqk vwjphcfzdr (igisnvstgy, sgrnljzvdi - xzuwaadkyj) View more | - | 25 Nov 2020 |